Francois Brisebois
Stock Analyst at Oppenheimer
(1.23)
# 2,504
Out of 4,479 analysts
67
Total ratings
30.77%
Success rate
-10.85%
Average return
Main Sectors:
24 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SVRA Savara | Maintains: Outperform | $11 → $15 | $4.64 | +223.28% | 3 | Jun 26, 2024 | |
| ADVM Adverum Biotechnologies | Initiates: Outperform | $25 | $6.97 | +258.68% | 1 | Jun 25, 2024 | |
| SLP Simulations Plus | Maintains: Outperform | $55 → $65 | $46.18 | +40.75% | 5 | Jun 13, 2024 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Outperform | $29 → $20 | $7.07 | +182.89% | 3 | May 13, 2024 | |
| ACHV Achieve Life Sciences | Maintains: Outperform | $18 → $11 | $4.78 | +130.13% | 5 | May 13, 2024 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $59 → $61 | $28.24 | +116.01% | 4 | May 9, 2024 | |
| DYN Dyne Therapeutics | Reiterates: Outperform | $47 | $35.49 | +32.43% | 4 | May 6, 2024 | |
| ALDX Aldeyra Therapeutics | Reiterates: Outperform | $10 | $3.25 | +207.69% | 2 | May 6, 2024 | |
| KALA Kala Pharmaceuticals | Reiterates: Outperform | $15 | $6.89 | +117.71% | 1 | Apr 1, 2024 | |
| DRRX DURECT | Reiterates: Outperform | $5 | $1.31 | +281.68% | 3 | Apr 1, 2024 | |
| DMAC DiaMedica Therapeutics | Reiterates: Outperform | $7 → $6 | $2.95 | +103.39% | 4 | Mar 21, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $27 → $29 | $14.12 | +105.38% | 7 | Mar 5, 2024 | |
| CYBN Cybin | Reiterates: Outperform | $4 | $0.27 | +1,409.43% | 2 | Aug 30, 2023 | |
| MDWD MediWound | Maintains: Outperform | $63 → $36 | $15.39 | +133.92% | 4 | Aug 17, 2023 | |
| HRMY Harmony Biosciences Holdings | Reiterates: Outperform | $69 | $30.42 | +126.82% | 4 | May 26, 2023 | |
| ICAD iCAD, Inc. | Maintains: Outperform | $5 → $4 | $1.27 | +216.21% | 3 | Apr 4, 2023 | |
| PCSA Processa Pharmaceuticals | Maintains: Outperform | $100 → $60 | $2.09 | +2,770.81% | 3 | Apr 3, 2023 | |
| BNGO Bionano Genomics | Maintains: Outperform | $120 → $90 | $0.66 | +13,489.01% | 2 | Feb 6, 2023 | |
| SNSE Sensei Biotherapeutics | Upgrades: Outperform | $5 | $0.60 | +740.34% | 1 | Oct 3, 2022 | |
| AQST Aquestive Therapeutics | Initiates: Outperform | $8.5 | $2.45 | +246.94% | 1 | Sep 7, 2022 | |
| SERA Sera Prognostics | Maintains: Outperform | $17 → $11 | $6.04 | +82.12% | 2 | Aug 29, 2022 | |
| MDXH MDxHealth | Assumes: Outperform | $18 | $2.36 | +662.71% | 1 | Jul 18, 2022 | |
| CMPS COMPASS Pathways | Initiates: Outperform | n/a | $5.95 | - | 1 | Oct 29, 2021 | |
| GLMD Galmed Pharmaceuticals | Initiates: Buy | n/a | $0.29 | - | 1 | Feb 4, 2020 |
Savara
Jun 26, 2024
Maintains: Outperform
Price Target: $11 → $15
Current: $4.64
Upside: +223.28%
Adverum Biotechnologies
Jun 25, 2024
Initiates: Outperform
Price Target: $25
Current: $6.97
Upside: +258.68%
Simulations Plus
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $46.18
Upside: +40.75%
Mind Medicine (MindMed)
May 13, 2024
Reiterates: Outperform
Price Target: $29 → $20
Current: $7.07
Upside: +182.89%
Achieve Life Sciences
May 13, 2024
Maintains: Outperform
Price Target: $18 → $11
Current: $4.78
Upside: +130.13%
Tarsus Pharmaceuticals
May 9, 2024
Maintains: Outperform
Price Target: $59 → $61
Current: $28.24
Upside: +116.01%
Dyne Therapeutics
May 6, 2024
Reiterates: Outperform
Price Target: $47
Current: $35.49
Upside: +32.43%
Aldeyra Therapeutics
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $3.25
Upside: +207.69%
Kala Pharmaceuticals
Apr 1, 2024
Reiterates: Outperform
Price Target: $15
Current: $6.89
Upside: +117.71%
DURECT
Apr 1, 2024
Reiterates: Outperform
Price Target: $5
Current: $1.31
Upside: +281.68%
DiaMedica Therapeutics
Mar 21, 2024
Reiterates: Outperform
Price Target: $7 → $6
Current: $2.95
Upside: +103.39%
Avadel Pharmaceuticals
Mar 5, 2024
Maintains: Outperform
Price Target: $27 → $29
Current: $14.12
Upside: +105.38%
Cybin
Aug 30, 2023
Reiterates: Outperform
Price Target: $4
Current: $0.27
Upside: +1,409.43%
MediWound
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $15.39
Upside: +133.92%
Harmony Biosciences Holdings
May 26, 2023
Reiterates: Outperform
Price Target: $69
Current: $30.42
Upside: +126.82%
iCAD, Inc.
Apr 4, 2023
Maintains: Outperform
Price Target: $5 → $4
Current: $1.27
Upside: +216.21%
Processa Pharmaceuticals
Apr 3, 2023
Maintains: Outperform
Price Target: $100 → $60
Current: $2.09
Upside: +2,770.81%
Bionano Genomics
Feb 6, 2023
Maintains: Outperform
Price Target: $120 → $90
Current: $0.66
Upside: +13,489.01%
Sensei Biotherapeutics
Oct 3, 2022
Upgrades: Outperform
Price Target: $5
Current: $0.60
Upside: +740.34%
Aquestive Therapeutics
Sep 7, 2022
Initiates: Outperform
Price Target: $8.5
Current: $2.45
Upside: +246.94%
Sera Prognostics
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $6.04
Upside: +82.12%
MDxHealth
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $2.36
Upside: +662.71%
COMPASS Pathways
Oct 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.95
Upside: -
Galmed Pharmaceuticals
Feb 4, 2020
Initiates: Buy
Price Target: n/a
Current: $0.29
Upside: -